- The final results of the APLICOV-PC study (Phase I-II), which were initially released last May and which the Company shared with the scientific community, demonstrate the safety of plitidepsin's use in patients with COVID-19 and postulate a positive therapeutic impact on the evolution of the disease.
- PharmaMar confirms in vitro activity of plitidepsin against several variants, including Delta and Omicron.
- The Life Science Alliance journal is co-founded by the Rockefeller University, the European Molecular Biology Organization (EMBO) and Cold Spring Harbor Laboratory.
MADRID, Jan. 11, 2022 /PRNewswire/ -- PharmaMar (MSE:PHM) has announced today the publication of an article in the Life Science Alliance journal, entitled "Pre-clinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19"[1] which includes a study on the in vitro activity of plitidepsin against the main SARS-CoV-2 variants, including the current Omicron variant.
According to the final data published in this article, plitidepsin has been shown to have a potent antiviral activity in all variants at very low (nanomolar) concentrations, with a positive in vitro therapeutic index. These studies were led by Dr. Adolfo Garcia-Sastre, Professor in the Department of Microbiology at the Icahn School of Medicine at Mount Sinai, New York, N.Y., USA.
Laboratory in vivo studies have also demonstrated a preferential distribution of plitidepsin to lung tissue, which is the organ primarily affected in patients with COVID-19. These studies showed a reduction in viral replication, resulting in a 99% decrease in viral loads in the lung of plitidepsin-treated animals.
The article also reviews data from the APLICOV-PC clinical trial, which demonstrated the safety of plitidepsin in patients with COVID-19 requiring hospital admission. The trial met the primary safety endpoint and showed clinical efficacy; in addition the study gathered consistent evidence of a plitidepsin mediated impact on viral load, on inflammatory pathways and on lymphopenia normalization.
In this Phase I-II study, 45 patients were enrolled, of whom 86.7% had moderate or severe disease. 41 patients (91%) had pneumonia, 32 (71% of the global sample) of them with bilateral pneumonia. Of note were the data observed in 23 patients with moderate disease, 74% of whom were discharged from hospital within the first week of treatment.
These results are the basis for the Phase III NEPTUNO clinical trial that is currently recruiting patients in 17 hospitals in Spain and 9 other countries mainly in Europe and Latin America.
José F. Varona, M.D., Ph.D., at the Department of Internal Medicine, Hospital Universitario HM Montepríncipe in Madrid has highlighted "our clinical impression with plitidepsin in the APLICOV-PC trial has been met, since in addition to satisfactorily meeting the safety objectives, we have observed in some cases an improvement in symptoms and objective data (microbiological parameters, oximetry parameters and radiological parameters) after administration of the drug."
Adolfo García-Sastre, Ph.D., professor at the Department of Microbiology at the Icahn School of Medicine at Mount Sinai, New York, commented, "It is noteworthy that the clinical data are consistent with the preclinical data, suggesting a benefit of plitidepsin administration to patients with COVID-19, and that, in pre-clinical models, plitidepsin has potent antiviral activity, not only for SARS-CoV-2 and its variants, including Delta and Omicron, but also against other coronaviruses."
José María Fernández Sousa-Faro, Ph.D., PharmaMar's Chairman stated "all the data we have seen so far with plitidepsin corroborate our initial hypothesis about its antiviral activity. In studies conducted both by PharmaMar and leading researchers from around the world, plitidepsin has demonstrated previously unseen potency against SARS-CoV-2. We hope that patient recruitment for the NEPTUNO trial will continue to progress, so that we can bring this treatment to all patients affected by the coronavirus and requiring hospitalization, as soon as possible. "
[1] https://www.life-science-alliance.org/content/5/4/e202101200
Media Contact:
Lara Vadillo – Communication Director lvadillo@pharmamar.com Mobile: +34 669471803Miguel Martínez-Cava – Communication Manager mmartinez-cava@pharmamar.com Mobile: +34 606597464Phone: +34 918466000
Capital Markets & Investor Relations:
José Luis Moreno– Capital Markets & Investor Relations Director
María Marín de la Plaza – Capital Markets & Investor Relationsinvestorrelations@pharmamar.comPhone: +34 914444500
Or please visit our website at pharmamar.com
